![Fernando Andreu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fernando Andreu
Vorstandsvorsitzender bei
2cureX ApS
Profil
Fernando Andreu is currently the Chief Executive Officer at 2cureX ApS.
Previously, he held the same position at 2cureX AB from 2021 to 2023.
He was also the Chief Executive Officer at Sysmex Inostics GmbH, Indivumed, Inc., and the Chief Business Officer at Indivumed GmbH.
Mr. Andreu received his undergraduate and MBA degrees from ESADE Business School.
Aktive Positionen von Fernando Andreu
| Unternehmen | Position | Beginn |
|---|---|---|
2cureX ApS
 2cureX ApS Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs and technology for the treatment of cancer | Vorstandsvorsitzender | 01.01.2021 |
Ehemalige bekannte Positionen von Fernando Andreu
| Unternehmen | Position | Ende |
|---|---|---|
| 2CUREX AB | Vorstandsvorsitzender | 29.12.2023 |
Sysmex Inostics GmbH
 Sysmex Inostics GmbH Miscellaneous Commercial ServicesCommercial Services Develops advanced genetic testing technologies | Vorstandsvorsitzender | - |
Indivumed GmbH
 Indivumed GmbH Data Processing ServicesTechnology Services Provides data & analytics of clinical bio specimens | Corporate Officer/Principal | - |
Indivumed, Inc.
 Indivumed, Inc. Electronic Equipment/InstrumentsElectronic Technology Founded in 2016, Indivumed, Inc. is a precision oncology biotech company dedicated to developing highly specific cancer therapies targeting unmet medical needs, particularly in colorectal cancer and other solid tumors such as non-small cell lung cancer. The company is based in Frederick, MD. The company leverages a proprietary multi-omics and clinical database, IndivuType, derived from standardized tumor samples collected through its clinical network. This platform integrates molecular, biological, technological, and pharmacological data, supported by advanced biomathematical and bioinformatic analyses and patient-derived tumor models, to identify and validate novel therapeutic targets. Indivumed advances both small molecule and biologic drug candidates through discovery, validation, and IND filing stages, and fosters collaboration via its Onco AI-Med network and research partnerships. | Vorstandsvorsitzender | - |
Ausbildung von Fernando Andreu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
6
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Indivumed GmbH
Indivumed GmbH Data Processing ServicesTechnology Services Provides data & analytics of clinical bio specimens | Technology Services |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs and technology for the treatment of cancer | Health Technology |
Sysmex Inostics GmbH
Sysmex Inostics GmbH Miscellaneous Commercial ServicesCommercial Services Develops advanced genetic testing technologies | Commercial Services |
2cureX AB
 2cureX AB Medical SpecialtiesHealth Technology Develops and supplies in vitro diagnostic (IVD) devices | Health Technology |
ESADE Business School
 ESADE Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Indivumed, Inc.
Indivumed, Inc. Electronic Equipment/InstrumentsElectronic Technology Founded in 2016, Indivumed, Inc. is a precision oncology biotech company dedicated to developing highly specific cancer therapies targeting unmet medical needs, particularly in colorectal cancer and other solid tumors such as non-small cell lung cancer. The company is based in Frederick, MD. The company leverages a proprietary multi-omics and clinical database, IndivuType, derived from standardized tumor samples collected through its clinical network. This platform integrates molecular, biological, technological, and pharmacological data, supported by advanced biomathematical and bioinformatic analyses and patient-derived tumor models, to identify and validate novel therapeutic targets. Indivumed advances both small molecule and biologic drug candidates through discovery, validation, and IND filing stages, and fosters collaboration via its Onco AI-Med network and research partnerships. | Electronic Technology |
